Fibroblast growth factor 21 (FGF21) analogs have significant therapeutic potential in metabolic dysfunction–associated steatohepatitis (MASH) but limited body weight effects in patients with MASH. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.